However, no significant relationships were observed among age (p = 0.797), sex (p = 0.600), histological type (p = 0.621), human epidermal growth factor receptor 2 status (p = 1.000), macroscopic classification (p = 0.058), primary tumor site (p = 1.000), peritoneal metastasis (p = 0.129), hematogenous metastasis (p = 0.613), lymphatic metastasis (p = 0.802), number of metastatic sites (p = 0.454), number of previous regimens (p = 0.551), and previous immune checkpoint inhibitor administered (p = 1.000) between the high- and low-CAR groups (Table 1). The gene discussed is ERBB2; the disease is neoplasm.